These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30667469)

  • 1. Estimates of the Number of Brand-name Drugs Affected by the Medicaid Rebate Cap in 2017.
    Dickson S
    JAMA Intern Med; 2019 Mar; 179(3):437-439. PubMed ID: 30667469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMS Rule Would Increase Cost Transparency of Medicaid-Covered Drugs.
    Harris E
    JAMA; 2023 Jun; 329(24):2118. PubMed ID: 37285174
    [No Abstract]   [Full Text] [Related]  

  • 3. Medicaid program; time limitation on recordkeeping requirements under the drug rebate program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2004 Nov; 69(227):68815-8. PubMed ID: 15565749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specialty Drugs - A Distinctly American Phenomenon.
    Naci H; Kesselheim AS
    N Engl J Med; 2020 Jun; 382(23):2179-2181. PubMed ID: 32492301
    [No Abstract]   [Full Text] [Related]  

  • 5. Medicaid payment for generic drugs: achieving savings and access.
    Peters CP
    Issue Brief George Wash Univ Natl Health Policy Forum; 2010 Sep; (839):1-16. PubMed ID: 20928958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
    Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
    J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Executive summary: pharmaceutical discounts under federal law: state program opportunities.
    von Oehsen WH; Ashe M; Duke K
    Am J Health Syst Pharm; 2003 Mar; 60(6):551-3. PubMed ID: 12659056
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicaid program; time limitation on price recalculations and recordkeeping requirements under the drug rebate program. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Aug; 68(168):51912-7. PubMed ID: 12962118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act.
    Bonakdar Tehrani A; Carroll NV
    Appl Health Econ Health Policy; 2017 Aug; 15(4):513-520. PubMed ID: 28224469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Will Ending the Medicaid Drug Rebate Cap Lower Drug Prices?
    Rome BN; Kesselheim AS
    JAMA Intern Med; 2021 Aug; 181(8):1034-1035. PubMed ID: 34180958
    [No Abstract]   [Full Text] [Related]  

  • 11. Value-Based Pricing and State Reform of Prescription Drug Costs.
    Hwang TJ; Kesselheim AS; Sarpatwari A
    JAMA; 2017 Aug; 318(7):609-610. PubMed ID: 28692713
    [No Abstract]   [Full Text] [Related]  

  • 12. Medicaid program; prescription drugs. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2007 Jul; 72(136):39141-245. PubMed ID: 17674494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trying to get control of drug costs, Florida earns kudos--and a lawsuit.
    Carlson B
    Manag Care; 2001 Oct; 10(10):17, 21. PubMed ID: 11764743
    [No Abstract]   [Full Text] [Related]  

  • 14. The pharmaceutical industry versus Medicaid--limits on state initiatives to control prescription-drug costs.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2004 Feb; 350(6):608-13. PubMed ID: 14762190
    [No Abstract]   [Full Text] [Related]  

  • 15. These doctor's mission: keeping drug costs down.
    Guglielmo WJ
    Med Econ; 2001 Apr; 78(8):108-10, 113-6. PubMed ID: 11386066
    [No Abstract]   [Full Text] [Related]  

  • 16. Limiting State Flexibility in Drug Pricing.
    Bagley N; Sachs RE
    N Engl J Med; 2018 Sep; 379(11):1002-1004. PubMed ID: 30207910
    [No Abstract]   [Full Text] [Related]  

  • 17. The Future of Drug-Pricing Transparency.
    Feldman WB; Rome BN; Avorn J; Kesselheim AS
    N Engl J Med; 2021 Feb; 384(6):489-491. PubMed ID: 33440087
    [No Abstract]   [Full Text] [Related]  

  • 18. Providers offer prescription for Medicaid drug-pricing law.
    Chaconas J
    Trustee; 1991 Dec; 44(12):12, 19. PubMed ID: 10115321
    [No Abstract]   [Full Text] [Related]  

  • 19. Government commitment and regulation of prescription drugs.
    Frank RG
    Health Aff (Millwood); 2003; 22(3):46-8. PubMed ID: 12757271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why California's Proposition 61 Was a Bad Idea.
    Yang YT; Chen B; Bennett CL
    Am J Med; 2017 Aug; 130(8):882-884. PubMed ID: 28454905
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.